The changing paradigm of thrombotic thrombocytopenic purpura

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 6, 2005, Pages 641-651

  Raife, Thomas J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

ADAMTS13; Hemoglobin; Microvascular thrombosis; Platelets; Thrombotic thrombocytopenic purpura (TTP); von Willebrand factor (vWF)

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ENDOTHELIUM CELL; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ENDOTHELIAL CELLS; HUMANS; MICROCIRCULATION; MODELS, CARDIOVASCULAR; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; STRESS, MECHANICAL; VON WILLEBRAND FACTOR;

EID: 30344472985     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-925470     Document Type: Review

References (103)

1. Kaplan B. Commentary on the relationships between HUS and TTP. In: Kaplan B, Trompeter R, Moake J, eds. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker; 1992:29-37
2. Remuzzi G. HUS and TTP: variable expression of a singe entity. Kidney Int 1987;32:292-308
3. Tsai H-M. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost2003;1:625-631
4. Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003;1:632-634
5. Moake J, Rudy C, Troll J. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307:1432-1435
6. Asada Y, Sumiyoshi A. Pathological features of thrombotic thrombocytopenic purpura. In: Kaplan B, Trompeter R, Moake J, eds. Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. New York: Marcel Dekker; 1992:491-498
7. Moake J, Turner N, Stathopoulos N, Nolasco L, Hellums J. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986;78:1456-1461
8. Moake J. Haemolytic-uraemic syndrome: basic science. Lancet 1994;343:393-397
9. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-4234
10. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244
11. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1385-1394
12. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998;339:1578-1584
13. Levy G, Nichols W, Lian E, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-494
14. Gerritsen H, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001;98:1654-1661
15. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001;98:1662-1666
16. Mannucci PM. Thrombotic thrombocytopenic purpura: a simpler diagnosis at last? Thromb Haemost 1999;82:1380-1381
17. Moore J, Hayward C, Warkentin T, Kelton J. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001;98:1842-1846
18. Vesely S, George J, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68
19. Remuzzi G, Galbusera M, Noris M, et al. von Willebrand factor cleaving protease ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002;100:778-785
20. Batlle J, Lopez-Fernandez M, Lopez-Borrasca A, et al. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 1987;70:173-176
21. Tsai HM, Kaul D, Lee T. Infusion of von Willebrand factor (vWf)-cleaving metalloproteinase enhances vWf proteolysis in mice. Blood 1999;94:249a (abst)
22. Dong J, Moake J, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-4039
23. Arya M, Anvari B, Romo G, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002;99:3971-3977
24. Dong J, Moake J, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-4039
25. Dong J, Moake J, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003;278: 29633-29639
26. Padilla A, Moake J, Bernardo A, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004;103:2150-2156
27. Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004; 103:1305-1310
28. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002;99:11902-11907
29. Schneppenheim R, Budde U, Oyen F, et al. Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003;101:1845-1850
30. Furlan M, Rubles R, Solenthaler M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-3103
31. Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-2846
32. Raife T, Atkinson B, Montgomery RR, Vesely S, Friedman K. Severe deficiency of von Willebrand factor-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44:146-150
33. Moake J. Moschcowitz, multimers and metalloprotease. N Engl J Med 1998;339:1629-1630
34. Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998;57:293-302
35. Karpman D, Lethagen S, Kristoffersson A, Isaksson C, von Holmberg L. Willebrand factor mediates increased platelet retention in recurrent thrombotic thrombocytopenic purpura. Thromb Haemost 1997;78:1456-1462
36. Ahn Y, Jy W, Kolodny L, et al. Activated platelet aggregates in thrombotic thrombocytopenic purpura: decrease with plasma infusions and normalization in remission. Br J Haematol 1996;95:408-415
37. Casonato A, Pontara E, Francesca S, et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002;99:180-184
38. Casonato A, Pontara E, Bertomoro A, et al. Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura. Am J Hematol 1996;51:7-11
39. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8-12
40. Fujimura Y, Matsumoto M, Yagi H, Yoshika A, Matsui T, von Titani K. Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002;75:25-34
41. Galbusera M, Ruggenenti P, Noris M, et al. Alpha 1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet 1995;345:224-225
42. Lester W, Williams M, Allford S, Enayat M, Machin S. Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y. Br J Haematol 2002;119:176-179
43. Allford S, Harrison P, Lawrie A, Liessner R, Mackie I, von Machin S. Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000;111:1215-1222
44. Doggett T, Girdhar G, Lawshe A, et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the Gp1bα-vWF tether bond. Biophys J 2002; 83:194-205
45. Huizinga E, Tsuji S, Romijn R, et al. Structures of glycoprotein 1bα and its complex with von Willebrand factor A1 domain. Science 2002;297:1176-1179
46. Montgomery RR. Structure and function of von Willebrand factor. In: Coleman R, Hirsh J, Marder V, Clowes A, George J, eds. Hemostasis and Thrombosis. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:249-274
47. ISTH VWF SSC Information Homepage. Available at: www.sheffield.ac.uk/vwf. Accessed November 22, 2005
48. Tsai H, Sussman I, Nagel R. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994;83:2171-2179
49. Kroll M, Hellums J, McIntire L, Schafer A, Moake J. Platelets and shear stress. Blood 1996;88:1525-1541
50. Pareti F, Lattuada A, Bressi C, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102:1290-1295
51. André P, Denis C, Ware J, et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000;96:3322-3328
52. Bernardo A, Ball C, Nolasco L, Moake J, Dong J. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004;104:100-106
53. Shariatmadar S, Nassiri M, Vincek V. Effect of plasma exchange on cytokines measured by multianalyte bead assay in thrombotic thrombocytopenic purpura. Am J Hematol 2005;79:83-88
54. Kwaan HC. Role of fibrinolysis in thrombotic thrombocytopenic purpura. Semin Hematol 1987;24:101-109
55. Byrnes J, Moake J, Klug P, Periman P. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990;34:169-174
56. Moake J, Byrnes J, Troll J, Rudy C, Hong S. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985;65: 1232-1236
57. Naumovski L, Pillsbury H. Treatment of thrombotic thrombocytopenic purpura with cryosupernatant. Am J Hematol 1991;38:250-251
58. Obrador G, Zeigler Z, Shadduck R, Rosenfeld CS, Hanrahan J. Effectiveness of cryosupernatant therapy in refractory and chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1993;42:217-220
59. Molinari E, Costamagna L, Perotti C, Isernia P, Pagani A, Salvaneschi L. Refractory thrombotic thrombocytopenic purpura: successful treatment by plasmapheresis with plasma supernatant. Haematologica (Budap) 1993;81:175-177
60. Centurioni R, Refe C, Cecapolli A. Cryosupernatant in thrombotic thrombocytopenic purpura (TTP): is it really useful? Haematologica (Budap) 1997;82:125-126
61. Sgarabotto D, Vianello F, Scano F, Stefani P, Sartori R, Girolami A. Clinical and laboratoristic remission after cryosupernatant plasma in thrombotic thrombocytopenic purpura. Haematologica (Budap) 1998;83:569-570
62. Ellis J, Theodossiou C, Schwarzenberger P. Treatment of thrombotic thrombocytopenic purpura with the cryosupernatant fraction of plasma: a case report and review of the literature. Am J Med Sci 1999;318:190-193
63. Bandarenko N, Brecher M, and the United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group. (US TTP ASG). Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apheresis 1998;13:133-141
64. Owens M, Sweeney JD, Tahhan R, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. J Clin Apheresis 1995;10:178-182
65. Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher Dial 2002;6:320-328
66. Rock G, Shumak K, Sutton D, Buskard N, Nair R. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:383-386
67. Zeigler Z, Shadduck R, Gryn J, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apheresis 2001;16:19-22
68. Yarranton H, Lawrie A, Purdy G, Mackie I, Machin S. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004;14:39-44
69. Roush K, Hillyer K, Barclay S, et al. vWF-cleaving metalloprotease (MP) activity: comparison of fresh frozen plasma (FFP), cryosupernatant (CS), and solvent detergent treated plasma (SDP). Transfusion 2001;41S:37S (abst)
70. Rock G, Ahluwalia N, Anderson D, et al. Metalloprotease levels are variably altered in thrombotic thrombocytopenic patients at presentation and after plasma exchange with either cryosupernatant plasma or fresh frozen plasma. Blood 2001;102:539a (abst)
71. Studt J-D, Hovinga J, Antoine G, Hermann M, Rieger M, Scheilflinger F. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005;105:542-544
72. Wada H, Kaneko T, Ohiwa M, et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993;44:101-105
73. Monteagudo J, Pereira A, Reverter JC, et al. Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Thromb Haemost 1991;66:515-519
74. Kobayashi M, Wada H, Wakita Y, et al. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995;73:10-14
75. Crawley JTB, Lam J, Rance J, Mollica L, O'Donnell J, Lane D. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005;105:1085-1093
76. Raife T, Friedman K, Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost 2004;92:387-393
77. Tsai H, Chandler L, Sarode R, et al. von Willebrand factor and von Willebrand factor-cleaving metalloproteinase activity in Escherichia coli 0157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001;49:653-659
78. Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996;87:3245-3254
79. Mitra D, Jaffe E, Weksler B, Hajjar K, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224-1234
80. Mitra D, Kim J, MacLow C, Karsan A, Laurence J. Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies. Am J Hematol 1998;59:279-287
81. Dang CT, Magid MS, Weksler B, Chadburn A, Laurence J. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura. Blood 1999;93:1264-1270
82. Mauro M, Kim J, Costello C, Laurence J. Role of transforming growth factor β 1 in microvascular endothelial cell apoptosis associated with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Am J Hematol 2001;66:12-22
83. Mauro M, Zlatopolskiy A, Raife T, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signaling cascades. Br J Haematol 2004;124:200-210
84. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988;8:5588-5592
85. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159-165
86. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: Comparison of transcriptional and posttranscriptional mechanisms. Blood 1991;77:542-550
87. Raife T, Lentz S, Atkinson B, Vesely S, Hessner M. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002;99:437-442
88. Raife TJ, McArthur J, Kisker T, Lentz SR. Remission after 13-cis retinoic acid in a case of refractory thrombotic thrombocytopenic purpura. Lancet 1998;352:454-455
89. Görner M, Seggewiss R, Schlenker T, Stremmel W, Ho A. A case of severe refractory thrombotic thrombocytopenic purpura responding to treatment with 13-cis retinoic acid. Br J Haematol 2002;117:249-250
90. Morse D, Choi A. Heme oxygenase-1. Am J Respir Cell Mol Biol 2002;27:8-16
91. Exner M, Minar E, Wagner O, Schillinger M. The role of hemo oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004;37:1097-1104
92. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002;99:11902-11907
93. Mannucci PM, Canciani M, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98: 2730-2735
94. Oleksowicz L, Niyati B, DeLeon-Fernandez. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999; 59:2244-2250
95. Motto D, Ginsburg D. Targeted ADAMTS13 deficiency in mice does not result in congenital thrombocytopenic purpura (TTP). 2004 Pediatric Academic Societies Meeting; May 1-4, 2004; San Francisco, CA
96. Raife T, Atkinson B, Montgomery RR, Vesely S, Friedman KD. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44:146-150
97. Pichette V, Querin S, Schurch W, Brun G, Lehner-Netsch G, Belage JM. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24:936-941
98. Richards A, Kemp E, Liszewski M, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003;100:12966-12971
99. Noris M, Ruggenenti P, Perna A, et al. Hypocomplementemia disdoses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. J Am Soc Nephrol 1999;10:281-293
100. Ying L, Katz Y, Schlesinger M, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 1999;65: 1538-1546
101. Buddies M, Donne R, Richards A, Goodship J, Goodship T. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet 2000;66:1721-1722
102. Geraghty M, Perlman E, Martin L, et al. Cobalamin C defect associated with hemolytic uremic syndrome. J Pediatr 1992;120:934-937
103. Van Hove J, Van Damme-Lombaerts R, Grunewald S, et al. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 2002;111: 195-201